Document is current
Any future updates will be listed below
-
Authors
Meca-Lallana, J.E.
Fernández-Prada, M.
García Vázquez, E.
Moreno Guillén, S.
Otero Romero, S.
Rus Hidalgo, M.
Villar Guimerans, L.M.
Eichau Madueño, S.
Fernández Fernández, Ó.
Izquierdo Ayuso, G.
Álvarez Cermeño, J.C.
Arnal García, C.
Arroyo González, R.
Brieva Ruiz, L.
Calles Hernández, C.
García Merino, A.
González Plata, M.
Hernández Pérez, M.Á.
Moral Torres, E.
Olascoaga Urtaza, J.
Oliva-Nacarino, P.
Oreja-Guevara, C.
Ortiz Castillo, R.
Oterino, A.
Prieto González, J.M.
Ramió-Torrentá, L.
Rodríguez-Antigüedad, A.
Saiz, A.
Tintoré, M.
Montalbán Gairin, X.
-
Funding
Funding for this research was provided by:
Bayer
Novartis Farmacéutica
Celgene
GlaxoSmithKline
AbbVie
Roche
Boehringer Ingelheim
Gilead Sciences
Merck Sharp and Dohme
Pfizer
ViiV Healthcare
Teva Pharmaceutical Industries
Bristol-Myers Squibb
Actelion Pharmaceuticals
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Journal Title: Neurología (English Edition)
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nrleng.2019.11.001
CrossRef DOI link to the associated document: https://doi.org/10.1016/j.nrl.2019.11.003
Content Type: article
Copyright: © 2019 Sociedad Española de Neurología. Published by Elsevier España, S.L.U.
